CYRX vs JBIO: stock comparison and AI forecast
Cryoport, Inc. (CYRX) and Jade Biosciences, Inc. (JBIO) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CYRX Cryoport, Inc.
- Price
- $17.29 +68.5% · 6M
- Market Cap
- $876M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
JBIO Jade Biosciences, Inc.
- Price
- $14.06 -42.4% · 6M
- Market Cap
- $894M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- CYRX and JBIO have similar market capitalizations ($876M and $894M).
- Over the last six months CYRX returned +68.5% and JBIO -42.4%.
- CYRX carries 0.54 times debt per unit of equity, against 0.07 times for JBIO.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CYRX | JBIO |
|---|---|---|
| Market Cap | $876M | $894M |
| P/B Ratio | 1.78x | 2.03x |
| EPS | $-0.85 | $-3.00 |
| Book Value/Share | $9.69 | $6.92 |
| Revenue/Share | $3.68 | – |
| FCF/Share | $-0.40 | – |
Profitability & Margins
| Metric | CYRX | JBIO |
|---|---|---|
| ROE | -6.9% | -42.9% |
| ROA | -4.5% | -40.0% |
| ROIC | -7.0% | -41.9% |
| Gross Margin | 47.1% | – |
| Operating Margin | -20.0% | – |
| Net Margin | -18.1% | – |
| EBT Margin | -15.4% | – |
| Tax Rate | -6.6% | -0.1% |
Financial Health
| Metric | CYRX | JBIO |
|---|---|---|
| Current Ratio | 2.08x | 14.93x |
| Quick Ratio | 1.98x | – |
| D/E Ratio | 0.54x | 0.07x |
| Financial Leverage | 1.54x | 1.07x |
| Interest Coverage | -13.8x | – |
| Working Capital | $239M | $440M |
Cash Flow
| Metric | CYRX | JBIO |
|---|---|---|
| Operating Cash Flow | $8M | -$124M |
| Free Cash Flow | -$20M | – |
| Capital Spending | -$28M | – |
| FCF/Sales | -10.7% | – |
| CapEx/Sales | 15.0% | – |
Operational Efficiency
| Metric | CYRX | JBIO |
|---|---|---|
| Asset Turnover | 0.25x | – |
| Receivables Turnover | 5.1x | – |
| Inventory Turnover | 4.6x | – |
| Fixed Assets Turnover | 2.0x | – |
| Days Sales Outstanding | 71 days | – |
| Days Inventory | 80 days | – |
Income Statement
| Metric | CYRX | JBIO |
|---|---|---|
| Total Revenue | $186M | – |
| Operating Income | -$37M | -$185M |
| Net Income | -$34M | -$189M |
| R&D Expense | $18M | $157M |
| SG&A Expense | $107M | – |
| Cost of Goods Sold | $99M | – |
Dividend & Shareholder Information
| Metric | CYRX | JBIO |
|---|---|---|
| Shares Outstanding | 51M | 64M |
| Net Income Growth | -144.7% | – |
| EPS Growth | -172.0% | – |
CYRX vs JBIO: stock comparison and AI forecast
Which is bigger, CYRX or JBIO?
CYRX and JBIO have similar market capitalizations ($876M and $894M).
Which stock performed better over the last six months, CYRX or JBIO?
Over the last six months CYRX returned +68.5% and JBIO -42.4%.
Which one does Intratio's AI model rank higher, CYRX or JBIO?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.